124 related articles for article (PubMed ID: 11425972)
41. [Cancer detection with whole-body FDG PET images without attenuation correction].
Yasuda S; Ide M; Takagi S; Shohtsu A; Mitomi T; Kobayashi S; Suzuki Y
Kaku Igaku; 1996 Apr; 33(4):367-73. PubMed ID: 8683875
[TBL] [Abstract][Full Text] [Related]
42. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
43. Usefulness of whole-body (18)F-FDG PET in patients with suspected metastatic brain tumors.
Jeong HJ; Chung JK; Kim YK; Kim CY; Kim DG; Jeong JM; Lee DS; Jung HW; Lee MC
J Nucl Med; 2002 Nov; 43(11):1432-7. PubMed ID: 12411544
[TBL] [Abstract][Full Text] [Related]
44. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
[TBL] [Abstract][Full Text] [Related]
45. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy--initial experience.
Blake MA; Slattery JM; Kalra MK; Halpern EF; Fischman AJ; Mueller PR; Boland GW
Radiology; 2006 Mar; 238(3):970-7. PubMed ID: 16505394
[TBL] [Abstract][Full Text] [Related]
46. Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease.
Graeber GM; Gupta NC; Murray GF
J Thorac Cardiovasc Surg; 1999 Apr; 117(4):719-27. PubMed ID: 10096967
[TBL] [Abstract][Full Text] [Related]
47. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies.
Shulkin BL; Mitchell DS; Ungar DR; Prakash D; Dole MG; Castle VP; Hernandez RJ; Koeppe RA; Hutchinson RJ
Radiology; 1995 Feb; 194(2):495-500. PubMed ID: 7824731
[TBL] [Abstract][Full Text] [Related]
48. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.
Abdel-Nabi H; Doerr RJ; Lamonica DM; Cronin VR; Galantowicz PJ; Carbone GM; Spaulding MB
Radiology; 1998 Mar; 206(3):755-60. PubMed ID: 9494497
[TBL] [Abstract][Full Text] [Related]
49. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison.
Agress H; Cooper BZ
Radiology; 2004 Feb; 230(2):417-22. PubMed ID: 14699176
[TBL] [Abstract][Full Text] [Related]
50. Depiction and characterization of liver lesions in whole body [¹⁸F]-FDG PET/MRI.
Beiderwellen K; Gomez B; Buchbender C; Hartung V; Poeppel TD; Nensa F; Kuehl H; Bockisch A; Lauenstein TC
Eur J Radiol; 2013 Nov; 82(11):e669-75. PubMed ID: 24011443
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of hemangioma by positron emission tomography: role in a multimodality approach.
Hatayama K; Watanabe H; Ahmed AR; Yanagawa T; Shinozaki T; Oriuchi N; Aoki J; Takeuchi K; Endo K; Takagishi K
J Comput Assist Tomogr; 2003; 27(1):70-7. PubMed ID: 12544246
[TBL] [Abstract][Full Text] [Related]
52. [Positron emission tomography (PET) with fludeoxyglucose F 18 in the study of adrenal masses: comparison of benign and malignant lesions].
Maurea S; Mainolfi C; Wang H; Varrella P; Panico MR; Klain M; Rossi R; Cremona F; Bazzicalupo L; Salvatore M
Radiol Med; 1996 Dec; 92(6):782-7. PubMed ID: 9122472
[TBL] [Abstract][Full Text] [Related]
53. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET.
Kole AC; Nieweg OE; Pruim J; Paans AM; Plukker JT; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
J Nucl Med; 1997 May; 38(5):692-6. PubMed ID: 9170429
[TBL] [Abstract][Full Text] [Related]
54. [Cancer screening with whole-body FDG PET].
Yasuda S; Ide M; Takagi S; Shohtsu A
Kaku Igaku; 1996 Oct; 33(10):1065-71. PubMed ID: 8952258
[TBL] [Abstract][Full Text] [Related]
55. Positron emission tomography imaging of musculoskeletal tumors in the shoulder girdle.
Suzuki H; Watanabe H; Shinozaki T; Yanagawa T; Suzuki R; Takagishi K
J Shoulder Elbow Surg; 2004; 13(6):635-47. PubMed ID: 15570232
[TBL] [Abstract][Full Text] [Related]
56. Dual-head gamma camera 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography in oncological patients: effects of non-uniform attenuation correction on lesion detection.
Zimny M; Kaiser HJ; Cremerius U; Reinartz P; Schreckenberger M; Sabri O; Buell U
Eur J Nucl Med; 1999 Aug; 26(8):818-23. PubMed ID: 10436193
[TBL] [Abstract][Full Text] [Related]
57. Comparison of FDG PET and positron coincidence detection imaging using a dual-head gamma camera with 5/8-inch NaI(Tl) crystals in patients with suspected body malignancies.
Boren EL; Delbeke D; Patton JA; Sandler MP
Eur J Nucl Med; 1999 Apr; 26(4):379-87. PubMed ID: 10199944
[TBL] [Abstract][Full Text] [Related]
58. Feasibility of a short acquisition protocol for whole-body positron emission tomography with fluorine-18 fluorodeoxyglucose.
Paul AK; Tatsumi M; Fujino K; Hashikawa K; Nishimura T
Eur J Nucl Med; 2001 Nov; 28(11):1697-701. PubMed ID: 11702113
[TBL] [Abstract][Full Text] [Related]
59. PET FDG studies in oncology.
Hawkins RA; Hoh CK
Nucl Med Biol; 1994 Jul; 21(5):739-47. PubMed ID: 9241650
[TBL] [Abstract][Full Text] [Related]
60. FDG-PET scanning after radiation can predict tumor regrowth three months later.
Koike I; Ohmura M; Hata M; Takahashi N; Oka T; Ogino I; Lee J; Umezawa T; Kinbara K; Watai K; Ozawa Y; Inoue T
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1231-8. PubMed ID: 14630256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
